Is a Kidney Biopsy Needed for IgA Nephropathy? Key Risks

To definitively confirm a diagnosis of primary IgA nephropathy (IgAN), a kidney biopsy is currently the medical standard ^[1][2]. However, this does not mean every person with suspected IgAN must have a biopsy immediately. While blood and urine tests provide essential clues about your kidney health, they cannot confirm the disease on their own ^[3]. A biopsy allows doctors to see the physical evidence of the disease, rule out other conditions, and understand how much damage has already occurred ^[4]. The decision to biopsy depends heavily on whether the results will actually change your treatment plan ^[5].

Why Blood and Urine Tests Are Not Enough

Blood and urine tests are the first steps in evaluating kidney disease ^[3]. Urine tests can detect proteinuria (protein in the urine) and hematuria (blood in the urine), which indicate kidney injury ^[6]. Blood tests measure creatinine to estimate your eGFR (estimated glomerular filtration rate), which tells your doctor how well your kidneys are filtering waste ^[3].

While these tests are excellent at estimating your current kidney function and assessing your risk for future kidney decline, they cannot prove that primary IgA nephropathy is the underlying cause ^[7]. Other conditions can cause identical blood and urine test results. Researchers are studying tests that measure galactose-deficient IgA1 (Gd-IgA1)—the abnormal protein involved in IgAN—but these tests are not yet reliable or specific enough to replace a biopsy ^[8][9].

What a Biopsy Reveals

A kidney biopsy provides three critical pieces of information that blood and urine tests cannot:

• Proof of IgA deposits: The defining feature of IgAN is the buildup of IgA antibodies in the filtering units of the kidneys (glomeruli). A biopsy is the only way to physically demonstrate these dominant IgA deposits ^[1]. Because IgA deposits can also appear in secondary conditions (like liver disease or infections), doctors must always look at the biopsy alongside your clinical history ^[10].
• Ruling out competing diagnoses: Other conditions, such as lupus nephritis or infection-related kidney diseases, can closely mimic IgA nephropathy ^[11][10]. A biopsy helps distinguish primary IgAN from these mimics, which often require completely different treatments.
• Assessing chronic damage and inflammation: Pathologists use a scoring system called the MEST-C score to grade the biopsy ^[4]. This score evaluates active inflammation (such as cellular buildup and crescents) and chronic damage like scarring (fibrosis) or tubular atrophy ^[4]. This information provides prognostic clues and is interpreted together with your kidney function, blood pressure, and protein levels to guide treatment decisions ^[12].

What the Procedure is Like and Pre-Biopsy Evaluation

Before a biopsy, your medical team will conduct a thorough evaluation. This typically includes checking your hemoglobin (to assess for anemia), platelet count, and coagulation profile (how well your blood clots) ^[13]. High blood pressure increases bleeding risk and must be adequately controlled to your team’s target before the procedure ^[5].

Medication Safety Warning: You will be asked about medications that increase bleeding risk, such as aspirin, NSAIDs, or blood thinners ^[14]. Never stop taking a prescribed medication or supplement on your own. Doing so can cause a stroke, clot, or other serious harm. Your medical team will provide explicit, individualized instructions on when to pause and restart these medications.

During a standard percutaneous (through the skin) biopsy, you will lie on your stomach and receive a local anesthetic to numb the area. A doctor will use real-time ultrasound to safely guide a thin needle to the kidney and take one or more tiny tissue samples ^[15].

What Are the Risks and Recovery?

Because the kidneys are highly vascular (full of blood vessels), the most common risk is bleeding ^[16]. According to large pooled studies of native-kidney biopsies:

• Common, minor issues: You may experience temporary soreness at the biopsy site (about 4% of patients). Small collections of blood around the kidney, called a hematoma, happen in about 11% of cases, but many are small and cause no symptoms ^[16]. It is somewhat common (around 3.5%) to have visible blood in your urine for a short time ^[16].
• Uncommon, serious complications: Major complications are rare. About 1.6% of patients may require a blood transfusion, and roughly 0.3% might need an invasive procedure to stop severe bleeding ^[16]. The risk of death directly attributed to a biopsy is extremely low (estimated at 0.06%) ^[16].

Your individual risk depends heavily on factors like your age, kidney function, and blood pressure ^[17][18].

Aftercare and Red Flags

After the procedure, you will typically be observed in bed for several hours to monitor for bleeding. You will be given activity restrictions, such as avoiding heavy lifting or driving for a few days. The exact recovery timeline and pathology report turnaround varies by hospital. Seek emergency medical care immediately if you develop:

• Heavy or persistent blood in your urine (or blood clots).
• Inability to urinate.
• Severe or worsening pain in your back, flank, or abdomen.
• Faintness, dizziness, or a fever.

When Might a Biopsy Be Deferred?

The decision to perform a biopsy is highly individualized. Your doctor might suggest delaying or avoiding a biopsy in several situations:

• Your risk of progression is low: If you have very minimal protein in your urine and excellent kidney function, your doctor might choose to simply monitor your urine and blood over time ^[19].
• The risks outweigh the benefits: If you have uncontrolled blood pressure, a severe bleeding disorder, or very small, scarred kidneys, a standard biopsy might be too dangerous ^[5][20]. In urgent cases, doctors might use alternative methods, like a transjugular biopsy (navigating through a vein in the neck) ^[5].
• Advanced age: While biopsies can be safely performed in older adults, doctors carefully weigh the risks and whether the results will actually change the treatment plan ^[21].

Conversely, a biopsy might be strongly recommended or expedited if you have an “atypical” presentation, such as a rapid decline in kidney function or sudden massive protein loss ^[5][22].